NeuImmune
NeuImmune, Inc. is an early-stage biotechnology company specializing in precision biologics through glyco- and cell-engineering. The company has developed the geCHO BioDesign platform, which includes a panel of glycoengineered CHO cells and AI tools to produce and optimize therapeutic glycoproteins with bespoke glycosylation profiles. NeuImmune also utilizes ICAM-1 targeting technology to enhance enzyme replacement therapies for lysosomal storage disorders, improving delivery to the CNS and visceral organs, reducing dosage and side effects. Their business model focuses on developing novel biologics for orphan diseases, leveraging proprietary platforms to address unmet medical needs with potential for broad application across lysosomal storage disorders. NeuImmune collaborates with partners like NIH, Novo Nordisk Foundation, Ginkgo Bioworks, and Kemp Proteins to advance their pipeline and technology development.
NeuImmune
NeuImmune, Inc. is an early-stage biotechnology company specializing in precision biologics through glyco- and cell-engineering. The company has developed the geCHO BioDesign platform, which includes a panel of glycoengineered CHO cells and AI tools to produce and optimize therapeutic glycoproteins with bespoke glycosylation profiles. NeuImmune also utilizes ICAM-1 targeting technology to enhance enzyme replacement therapies for lysosomal storage disorders, improving delivery to the CNS and visceral organs, reducing dosage and side effects. Their business model focuses on developing novel biologics for orphan diseases, leveraging proprietary platforms to address unmet medical needs with potential for broad application across lysosomal storage disorders. NeuImmune collaborates with partners like NIH, Novo Nordisk Foundation, Ginkgo Bioworks, and Kemp Proteins to advance their pipeline and technology development.